

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangsu Hengrui Pharmaceuticals Co., Ltd.

江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to the disclosure requirements under Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

According to the relevant regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the “**Company**”) had published an announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn). The following is a translation of the abovementioned announcement solely for reference only. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
December 7, 2025

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Dong Jiahong, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Announcement on the Inclusion of Company's Drugs
in the National Reimbursement Drug List (NRDL)

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein.

In accordance with the Notice on Issuing the National Drug Catalog for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (2025) (the “National Drug Catalog for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance”, hereinafter referred to as the “NRDL”) jointly issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, certain drugs of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (hereafter referred to as “Hengrui” or the “Company”) have been included in the NRDL.

Through NRDL related negotiations, trastuzumab rezetecan for Injection, Famitinib Malate Capsules, Vunakizumab Injection, Ivarmacitinib Sulfate Tablets, Fosrolapitant and Palonosetron Hydrochloride for Injection, Recaticimab for Injection, Abiraterone Acetate Tablets (II), Irinotecan Hydrochloride Liposome Injection (II), Retaglipitin Phosphate and Metformin Hydrochloride Tablets (I)/(II), and Perfluorohexyloctane Eye Drops were included in the NRDL for the first time; newly added indication of Camrelizumab for Injection, Fluzoparib Capsules, and Tegileridine Fumarate Injection were successfully included in the NRDL; Pyrotinib Malate Tablets, Hetrombopag Olamine Tablets, Reglidine Phosphate Tablets, Remimazolam Tosilate for Injection, and Mecapegfilgrastim Injection were successfully renewed in the NRDL;

Apatinib Mesylate Tablets and Bupivacaine Liposome Injection had new indication moved to regular catalog for management. The specific situation is as follows:

I. Drug inclusion in the NRDL

Serial no.	Common name of drug	Dosage form	Reimbursed indication	Approval Date	Format of negotiation
1	Trastuzumab Rezetecan for Injection	Injection	This product, as a monotherapy, is indicated for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring human epidermal growth factor receptor 2 (HER2) activating mutations and have received at least one prior systemic therapy.	May 2025	First-time inclusion
2	Famitinib Malate Capsules	Capsules	Famitinib Malate in combination with Camrelizumab for Injection is indicated for patients with recurrent or metastatic cervical cancer who have previously failed platinum-based chemotherapy but have not received bevacizumab treatment.	May 2025	First-time inclusion
3	Vunakizumab Injection	Injection	1. Indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. 2. Indicated for the treatment of adult patients with active ankylosing spondylitis who have had an inadequate response to conventional therapy.	August 2024	First-time inclusion
4	Ivamacitinib Sulfate Tablets	Tablets	1. Adults with active ankylosing spondylitis who have shown inadequate efficacy or intolerance to one or more TNF inhibitors. 2. Adults with moderate-to-severe active rheumatoid arthritis who have shown inadequate efficacy or intolerance to one or more TNF inhibitors. 3. Adults with moderate-to-severe atopic dermatitis who showed inadequate efficacy or intolerance to	March 2025	First-time inclusion

			topical treatment or other systemic therapies.		
5	Fosrolapitant and Palonosetron Hydrochloride for Injection	Injection	This product is indicated for the prevention of acute and delayed nausea and vomiting caused by highly emetogenic chemotherapy (HEC) in adults.	May 2025	First-time inclusion
6	Recaticimab for Injection	Injection	Indicated for use in combination with a statin, or a statin with other lipid-lowering therapies, on a background of diet control, in adult patients with primary hypercholesterolemia (including heterozygous familial and non-familial hypercholesterolemia) or mixed dyslipidemia who have not achieved their LDL-C goals despite receiving moderate- or high-intensity statin therapy; or as monotherapy in adult patients with non-familial hypercholesterolemia or mixed dyslipidemia to reduce LDL-C, total cholesterol (TC), and apolipoprotein B (Apo B) levels.	January 2025	First-time inclusion
7	Abiraterone Acetate Tablets (II)	Tablets	This product is used in combination with prednisone or prednisolone to treat: 1. Metastatic castration-resistant prostate cancer (mCRPC). 2. Indicated for the treatment of newly diagnosed, high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in patients who are endocrine therapy-naïve or have received endocrine therapy for no more than 3 months.	December 2023	First-time inclusion
8	Irinotecan Hydrochloride Liposome Injection (II)	Injection	This product is used in combination with fluorouracil and calcium folinate for the treatment of patients with unresectable locally advanced or metastatic pancreatic carcinoma who have progressed following prior gemcitabine-based chemotherapy.	December 2023	First-time inclusion

9	Retaglipitin Phosphate and Metformin Hydrochloride Tablets (I)/(II)	Tablets	This product, in combination with diet and exercise, is indicated for the improvement of glycemic control in adult patients with type 2 diabetes who are candidates for treatment with reglidine phosphate and metformin hydrochloride.	May 2025	First-time inclusion
10	Perfluorohexyloctane Eye Drops	Ophthalmic formulation	Indicated for the treatment of dry eyes associated with meibomian gland dysfunction.	June 2025	First-time inclusion
11	Camrelizumab for Injection	Injection	<p>1. Indicated for the treatment of advanced hepatocellular carcinoma after sorafenib and/or lenvatinib treatment and/or oxaliplatin-containing chemotherapy.</p> <p>2. Indicated for combination with pemetrexed+carboplatin for unresectable locally advanced or metastatic EGFR-mut negative ALK negative 1L non-small cell lung cancer</p> <p>3. Indicated for locally advanced or metastatic esophageal squamous cell carcinoma progressed after or intolerable to 1L chemotherapy.</p> <p>4. Indicated for the treatment of advanced nasopharyngeal carcinoma progressed after or intolerable to 2L+chemotherapy</p> <p>5. Indicated for combination with cisplatin+gemcitabine for 1L locally relapsed or metastatic nasopharyngeal carcinoma.</p> <p>6. Indicated for combination with cisplatin+paclitaxel for 1L unresectable locally advanced/relapsed or metastatic esophageal squamous cell carcinoma.</p> <p>7. Indicated for combination with carboplatin +paclitaxel for 1L locally advanced or metastatic squamous non-small cell lung cancer.</p> <p>8. Indicated for combination with Apatinib for 1L unresectable or metastatic hepatocellular carcinoma.</p> <p>9. Famitinib Malate in combination with Camrelizumab for Injection is</p>	May 2019	Added new indication (item 9)

			indicated for patients with recurrent or metastatic cervical cancer who have previously failed platinum-based chemotherapy but have not received bevacizumab treatment.		
12	Fluzoparib Capsules	Capsules	<p>1. Indicated for the treatment of patients with platinum-sensitive recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer harboring germline BRCA mutation (gBRCAm) who have undergone second-line or above chemotherapy.</p> <p>2. Indicated for the maintenance treatment of platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in adult patients who are in a complete or partial response to platinum-based chemotherapy.</p> <p>3. Indicated for the maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in adult patients who are in a complete or partial response to first-line platinum-based chemotherapy.</p> <p>4. Indicated for monotherapy or in combination with apatinib mesylate for the treatment of human epidermal growth factor receptor (HER2)-negative metastatic breast cancer with germline BRCA mutation (gBRCAm) in adult patients who have received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer must have previously received endocrine therapy or be deemed unsuitable for endocrine therapy.</p>	December 2020	Added new indication (item 4)
13	Apatinib Mesylate Tablets	Tablets	1. This product is indicated as monotherapy for the treatment of patients with advanced gastric or	October 2014	Added new indication (item 4) and

			<p>gastroesophageal junction adenocarcinoma who have progressed or relapsed after at least two prior lines of systemic chemotherapy; Patients should be in generally good condition when receiving treatment.</p> <p>2. This product is indicated as monotherapy for the treatment of patients with advanced hepatocellular carcinoma who have failed or are intolerant to at least first-line systemic therapy;</p> <p>3. This product is indicated in combination with camrelizumab for Injection for the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma; and</p> <p>4. This product, in combination with fluzoparib, is indicated for adult patients with germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer previously treated with chemotherapy in neoadjuvant, adjuvant, or metastatic settings, and for whom patients with HR-positive disease have received prior endocrine therapy or are unsuitable for it.</p>		adjusted to routine catalog for management
14	Tegileridine Fumarate Injection	Injection	This product is indicated for the treatment of moderate to severe postoperative pain.	January 2024	New indication (combined description)
15	Pyrotinib Maleate Tablets	Tablets	<p>1. This product is used in combination with capecitabine, indicated for the treatment of epidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic breast cancer in patients who have not previously received or have previously received trastuzumab.</p> <p>2. This product is used in combination with trastuzumab and docetaxel, indicated for the</p>	August 2018	Renewal

			<p>treatment of HER2-positive recurrent or metastatic breast cancer in patients who have not received prior anti-HER2 therapy in the advanced stage.</p> <p>3. This product is used in combination with trastuzumab and docetaxel, indicated for the neoadjuvant treatment of HER2-positive early-stage or locally advanced breast cancer.</p>		
16	Hetrombopag Olamine Tablets	Tablets	<p>1. This product is indicated for the treatment of adult patients with chronic primary immune thrombocytopenia (ITP) who have had an insufficient response to glucocorticoids or immunoglobulins.</p> <p>2. This product is indicated for the treatment of adult patients with severe aplastic anemia (SAA) who have had an inadequate response to immunosuppressive therapy (IST).</p>	June 2021	Renewal
17	Retagliptin Phosphate Tablets	Tablets	<p>This product is indicated for improvement of glycemic control in adult patients with type 2 diabetes mellitus.</p> <p>monotherapy: This product is indicated as monotherapy as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus.</p> <p>This product is used in combination with metformin hydrochloride: This product can be used in combination with metformin hydrochloride as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus when adequate glycemic control is not achieved with metformin hydrochloride monotherapy.</p>	June 2023	Renewal

18	Remimazolam Tosilate for Injection	Injection	1.Non-intubated surgeries/procedures. 2. Induction and maintenance of general anesthesia.	December 2019	Renewal
19	Mecapegfilgrastim Injection	Injection	This product is indicated for the reduction of the incidence of infection manifested by febrile neutropenia in adult patients with non-myeloid malignant tumors when treated with myelosuppressive anticancer drugs that are prone to causing febrile neutropenia. This product is not indicated for the mobilization of peripheral blood progenitor cells in hematopoietic stem cell transplantation.	May 2018	Renewal
20	Bupivacaine Liposome Injection	Injection	1. Indicated for postoperative local analgesia via single-dose infiltration in patients aged 12 years and older. 2. Indicated for postoperative regional analgesia via interscalene brachial plexus block in adult patients. 3. Indicated for postoperative regional analgesia via popliteal sciatic nerve block in adult patients. 4. Indicated for postoperative regional analgesia via adductor canal block in adult patients.	December 2022	Added new indication (item 3 and 4) and adjusted to routine catalog for management

II. Impact on the Company

The total sales of the Company's above drugs were approximately RMB 8.66 billion in the full year of 2024, and approximately RMB 7.55 billion in the first three quarters of 2025. The inclusion of the Company's above drugs in the NRDL will facilitate their sales, and its impact on the Company's business performance cannot be estimated for the time being. The NRDL (2025) will be officially implemented from January 1, 2026. The payment standards, reimbursement details, and other related information for medical insurance shall be subject to the official announcements from the National Healthcare Security Administration and other relevant government authorities. Investors are kindly advised to make prudent decisions and pay attention to

investment risks.

Notice is hereby given.

Board of Directors of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

December 7, 2025